{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:41:18Z","timestamp":1793036478605,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Foundation of Guangxi, China","award":["(No. 2021JJA140122)."],"award-info":[{"award-number":["(No. 2021JJA140122)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00228-024-03795-2","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T05:07:48Z","timestamp":1734930468000},"page":"365-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug\u2013drug interaction of phenytoin sodium and methylprednisolone on voriconazole: a population pharmacokinetic model in children with thalassemia undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"81","author":[{"given":"Yun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-lu","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-yun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-ru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-da","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-920X","authenticated-orcid":false,"given":"Taotao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"3795_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0140-6736(82)90319-1","volume":"2","author":"ED Homas","year":"1982","unstructured":"Homas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, de Stefano P, Sullivan KM, Clift RA, Storb R (1982) Marrow transplantation for thalassaemia. Lancet 2:227\u2013229. https:\/\/doi.org\/10.1016\/s0140-6736(82)90319-1","journal-title":"Lancet"},{"key":"3795_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/sj.bmt.1705856","volume":"40","author":"A Bjorklund","year":"2007","unstructured":"Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, Ljungman P (2007) Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 40:1055\u20131062. https:\/\/doi.org\/10.1038\/sj.bmt.1705856","journal-title":"Bone Marrow Transplant"},{"key":"3795_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.bbmt.2013.05.018","volume":"19","author":"AK Omer","year":"2013","unstructured":"Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, Mylonakis E, Ballen KK (2013) Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant 19:1190\u20131196. https:\/\/doi.org\/10.1016\/j.bbmt.2013.05.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"3795_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1631\/jzus.B1500005","volume":"16","author":"JM Shi","year":"2015","unstructured":"Shi JM, Pei XY, Luo Y, Tan YM, Tie RX, He JS, Zheng WY, Zhang J, Cai Z, Lin MF, Huang H (2015) Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B 16:796\u2013804. https:\/\/doi.org\/10.1631\/jzus.B1500005","journal-title":"J Zhejiang Univ Sci B"},{"key":"3795_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","volume":"51","author":"J Schulz","year":"2019","unstructured":"Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C (2019) Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev 51:247\u2013265. https:\/\/doi.org\/10.1080\/03602532.2019.1632888","journal-title":"Drug Metab Rev"},{"key":"3795_CR6","doi-asserted-by":"publisher","first-page":"e01194","DOI":"10.1128\/AAC.01194-17","volume":"62","author":"S Gastine","year":"2018","unstructured":"Gastine S, Lehrnbecher T, Muller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G (2018) Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children. Antimicrob Agents Chemother 62:e01194-e1217. https:\/\/doi.org\/10.1128\/AAC.01194-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR7","doi-asserted-by":"publisher","unstructured":"Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA, Averbuch D, Castagnola E, Cesaro S, Engelhard D, Garcia-Vidal C, Kanerva J, Ritz N, Roilides E, Styczynski J, Warris A, Lehrnbecher T (2021) 8th European conference on infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 22:e254\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(20)30723-3","DOI":"10.1016\/S1470-2045(20)30723-3"},{"key":"3795_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1111\/bcp.14661","volume":"87","author":"E Gautier-Veyret","year":"2021","unstructured":"Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, Bolcato L, Depeisses J, Schacherer M, Schummer G, Fonrose X, Stanke-Labesque F (2021) Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol 87:2534\u20132541. https:\/\/doi.org\/10.1111\/bcp.14661","journal-title":"Br J Clin Pharmacol"},{"key":"3795_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649\u2013663. https:\/\/doi.org\/10.2165\/00003088-200645070-00002","journal-title":"Clin Pharmacokinet"},{"key":"3795_CR10","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/antibiotics10121542","volume":"10","author":"YC Zhao","year":"2021","unstructured":"Zhao YC, Zou Y, Hou JJ, Xiao CL, Zhang BK, Li JK, Xiang DX, Sandaradura I, Yan M (2021) Factors affecting voriconazole trough concentration and optimal maintenance voriconazole dose in Chinese children. Antibiotics (Basel) 10:1542. https:\/\/doi.org\/10.3390\/antibiotics10121542","journal-title":"Antibiotics (Basel)"},{"key":"3795_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/antibiotics9090574","volume":"9","author":"B Khan-Asa","year":"2020","unstructured":"Khan-Asa B, Punyawudho B, Singkham N, Chaivichacharn P, Karoopongse E, Montakantikul P, Chayakulkeeree M (2020) Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in Thai patients with hematologic diseases. Antibiotics (Basel) 9:574. https:\/\/doi.org\/10.3390\/antibiotics9090574","journal-title":"Antibiotics (Basel)"},{"key":"3795_CR12","doi-asserted-by":"publisher","first-page":"106750","DOI":"10.1016\/j.ijantimicag.2023.106750","volume":"61","author":"DA van den Born","year":"2023","unstructured":"van den Born DA, Martson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, Sturkenboom MGG, Touw DJ (2023) Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents 61:106750. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106750","journal-title":"Int J Antimicrob Agents"},{"key":"3795_CR13","doi-asserted-by":"publisher","first-page":"e0020721","DOI":"10.1128\/AAC.00207-21","volume":"65","author":"X Tian","year":"2021","unstructured":"Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X (2021) Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother 65:e0020721. https:\/\/doi.org\/10.1128\/AAC.00207-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR14","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for medical mycology. J Antimicrob Chemother 69:1162\u20131176. https:\/\/doi.org\/10.1093\/jac\/dkt508","journal-title":"J Antimicrob Chemother"},{"key":"3795_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","volume":"40","author":"K Chen","year":"2018","unstructured":"Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S (2018) Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. Ther Drug Monit 40:663\u2013674. https:\/\/doi.org\/10.1097\/FTD.0000000000000561","journal-title":"Ther Drug Monit"},{"key":"3795_CR16","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/bcp.14578","volume":"87","author":"D Tang","year":"2021","unstructured":"Tang D, Yan M, Song BL, Zhao YC, Xiao YW, Wang F, Liang W, Zhang BK, Chen XJ, Zou JJ, Tian Y, Wang WL, Jiang YF, Gong GZ, Zhang M, Xiang DX (2021) Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study. Br J Clin Pharmacol 87:1890\u20131902. https:\/\/doi.org\/10.1111\/bcp.14578","journal-title":"Br J Clin Pharmacol"},{"key":"3795_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1046\/j.1523-1755.2003.00208.x","volume":"64","author":"A Pierrat","year":"2003","unstructured":"Pierrat A, Gravier E, Saunders C, Caira MV, A\u00eft-Djafer Z, Legras B, Malli\u00e9 JP (2003) Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 64:1425\u20131436. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00208.x","journal-title":"Kidney Int"},{"key":"3795_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1651-2227.2011.02580.x","volume":"101","author":"R El Edelbi","year":"2012","unstructured":"El Edelbi R, Lindemalm S, Eksborg S (2012) Estimation of body surface area in various childhood ages\u2013validation of the Mosteller formula. Acta Paediatr 101:540\u2013544. https:\/\/doi.org\/10.1111\/j.1651-2227.2011.02580.x","journal-title":"Acta Paediatr"},{"key":"3795_CR19","doi-asserted-by":"publisher","first-page":"e01194","DOI":"10.1128\/AAC.01194-17","volume":"62","author":"S Gastine","year":"2017","unstructured":"Gastine S, Lehrnbecher T, M\u00fcller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G (2017) Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children. Antimicrob Agents Chemother 62:e01194-e1217. https:\/\/doi.org\/10.1128\/AAC.01194-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2017","unstructured":"Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Ag\u00fandez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ (2017) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther 102:45\u201351. https:\/\/doi.org\/10.1002\/cpt.583","journal-title":"Clin Pharmacol Ther"},{"key":"3795_CR21","doi-asserted-by":"publisher","first-page":"e0062321","DOI":"10.1128\/AAC.00623-21","volume":"65","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Mohamud MA, Smith AR, Jacobson PA, Jaber MM, Alharbi AF, Fisher J, Kirstein MN (2021) CYP2C19 Phenotype and body weight-guided voriconazole initial dose in infants and children after hematopoietic cell transplantation. Antimicrob Agents Chemother 65:e0062321. https:\/\/doi.org\/10.1128\/AAC.00623-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR22","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1128\/AAC.05761-11","volume":"56","author":"LE Friberg","year":"2012","unstructured":"Friberg LE, Ravva P, Karlsson MO, Liu P (2012) Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 56:3032\u20133042. https:\/\/doi.org\/10.1128\/AAC.05761-11","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1208\/s12248-012-9407-9","volume":"14","author":"XS Xu","year":"2012","unstructured":"Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A (2012) Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J 14:927\u2013936. https:\/\/doi.org\/10.1208\/s12248-012-9407-9","journal-title":"AAPS J"},{"key":"3795_CR24","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","volume":"48","author":"TJ Walsh","year":"2004","unstructured":"Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48:2166\u20132172. https:\/\/doi.org\/10.1128\/AAC.48.6.2166-2172.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","volume":"58","author":"C Shi","year":"2019","unstructured":"Shi C, Xiao Y, Mao Y, Wu J, Lin N (2019) Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet 58:687\u2013703. https:\/\/doi.org\/10.1007\/s40262-019-00735-7","journal-title":"Clin Pharmacokinet"},{"key":"3795_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/jcpt.1380","volume":"47","author":"Y Wu","year":"2022","unstructured":"Wu Y, Lv C, Wu D, Qi J, Cai R, Zhou S, Li C, Wei Y, Liu T (2022) Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics. J Clin Pharm Ther 47:2245\u20132254. https:\/\/doi.org\/10.1111\/jcpt.1380","journal-title":"J Clin Pharm Ther"},{"key":"3795_CR27","doi-asserted-by":"publisher","first-page":"e0049321","DOI":"10.1128\/AAC.00493-21","volume":"65","author":"J Wang","year":"2021","unstructured":"Wang J, Xu H, Li R, Wu S, Zou J, Wang Y (2021) Model-oriented dose optimization of voriconazole in critically Ill children. Antimicrob Agents Chemother 65:e0049321. https:\/\/doi.org\/10.1128\/AAC.00493-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/jcph.2024","volume":"62","author":"T Takahashi","year":"2022","unstructured":"Takahashi T, Jaber MM, Smith AR, Jacobson PA, Fisher J, Kirstein MN (2022) Predictive value of C-reactive protein and albumin for temporal within-individual pharmacokinetic variability of voriconazole in pediatric patients undergoing hematopoietic cell transplantation. J Clin Pharmacol 62:855\u2013862. https:\/\/doi.org\/10.1002\/jcph.2024","journal-title":"J Clin Pharmacol"},{"key":"3795_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/AAC.00751-08","volume":"53","author":"MO Karlsson","year":"2009","unstructured":"Karlsson MO, Lutsar I, Milligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935\u2013944. https:\/\/doi.org\/10.1128\/AAC.00751-08","journal-title":"Antimicrob Agents Chemother"},{"key":"3795_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2125.2009.03464.x","volume":"68","author":"JW Alffenaar","year":"2009","unstructured":"Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM (2009) Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage. Br J Clin Pharmacol 68:462\u2013463. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03464.x","journal-title":"Br J Clin Pharmacol"},{"key":"3795_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40268-021-00365-0","volume":"21","author":"K Suetsugu","year":"2021","unstructured":"Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, Miyamoto T, Egashira N, Akashi K, Ieiri I (2021) Effects of letermovir and\/or methylprednisolone coadministration on voriconazole pharmacokinetics in hematopoietic stem cell transplantation: a population pharmacokinetic study. Drugs R D 21:419\u2013429. https:\/\/doi.org\/10.1007\/s40268-021-00365-0","journal-title":"Drugs R D"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03795-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:12:11Z","timestamp":1739430731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03795-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3795"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03795-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved the protocol (NO.2022-KY-031). This study complied with the Declaration of Helsinki and national and institutional standards and informed consent was obtained from legal guardians before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript. All authors agreed to publish this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}